LQT Therapeutics closes US$19 million Series A financing
On August 10, 2021, LQT Therapeutics, Inc. (LQTT) announced the successful completion of a US$19 million Series A financing. The financing was led by Amplitude Ventures and included new investments from Lumira Ventures, Amzak Health, Alexandria Venture Investments, founding investor Fonds de solidarité FTQ, founding scientists and members of the management team.
As part of the financing Jean-François Pariseau from Amplitude Ventures, Daniel Hétu, MD from Lumira Ventures, and Scott Weiner from Amzak Health will join the Board of Directors.
Further information can be found on Canada Newswire’s website.
LQT Therapeutics, launched in 2019 by the Fonds de solidarité FTQ, is pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias based on research from Beth Israel Deacons Medical Center, Massachusetts General Hospital, and Sanofi, S.A. By combining leading-edge cardiovascular genetics and diagnostics with recent advances in the understanding of the role of SGK1, LQT Therapeutics seeks to make a meaningful difference in the lives of people suffering from Long QT Syndrome and resistant cancers.
Amplitude Ventures is a full-stack venture capital firm using a unique growth model to build Canadian companies with world-class management teams and scale companies to breakout potential. With over C$300 million under management and offices in Montreal, Toronto and Vancouver, Amplitude applies a proven, evidence-based approach to investing in leading precision medicine companies.